Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
NCT00251225Phase 2Completed
- Start
- Aug 2005
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in prostate cancer (PCa). Primary endpoint: Overall Time To Progression at 24 months. Started Aug 2005; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00251225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251225.